Pfizer cans PF-08046045, but keeps PF-08046044 for now.
ApexOnco Front Page
Recent articles
Bristol will advance the newest pivotal trials, in first-line colorectal and gastric cancers.
But BeOne canned its alcestobart deal in May.
Tiragolumab failed the Skyscraper-14 and 03 studies, Roche quietly reveals.
Biopharma's interest in CDH17 and CDH6 continues, courtesy of Lepu and Qilu.
The company claims a 69% response rate with iSCIB1+, but only in a “target population”.
There are questions about vuso-vec’s supporting and confirmatory trials.
The Bristol/Merck’s drug’s hopes in myelofibrosis have taken a blow.
